Agilent Technologies (A) Rating Reiterated by Robert W. Baird
Robert W. Baird restated their buy rating on shares of Agilent Technologies (NYSE:A) in a report issued on Thursday. The firm currently has a $76.00 price target on the medical research company’s stock.
A number of other equities analysts also recently issued reports on the company. Barclays reiterated a buy rating and set a $74.00 price target on shares of Agilent Technologies in a research report on Monday, January 8th. Evercore ISI assumed coverage on Agilent Technologies in a research report on Wednesday, January 3rd. They set an outperform rating and a $75.00 price target on the stock. ValuEngine downgraded Agilent Technologies from a buy rating to a hold rating in a research report on Friday, December 1st. Cowen restated a hold rating and issued a $70.00 target price on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Finally, JPMorgan Chase & Co. raised their target price on Agilent Technologies to $75.00 and gave the company an overweight rating in a research report on Tuesday, November 21st. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $69.25.
Agilent Technologies (A) opened at $73.07 on Thursday. The stock has a market capitalization of $23,520.00, a P/E ratio of 34.96, a price-to-earnings-growth ratio of 2.21 and a beta of 1.28. The company has a current ratio of 3.30, a quick ratio of 2.85 and a debt-to-equity ratio of 0.37. Agilent Technologies has a 1 year low of $47.05 and a 1 year high of $73.21.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be issued a $0.149 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend is Friday, December 29th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s dividend payout ratio (DPR) is currently 28.71%.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $68.77, for a total transaction of $1,546,018.37. Following the completion of the sale, the chief executive officer now owns 336,637 shares of the company’s stock, valued at $23,150,526.49. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Patrick Kaltenbach sold 7,358 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $69.28, for a total value of $509,762.24. Following the sale, the insider now directly owns 72,862 shares of the company’s stock, valued at approximately $5,047,879.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 198,141 shares of company stock valued at $13,830,045.
Hedge funds have recently bought and sold shares of the business. TimesSquare Capital Management LLC purchased a new position in shares of Agilent Technologies during the third quarter worth $58,550,000. Voya Investment Management LLC boosted its position in shares of Agilent Technologies by 444.0% during the second quarter. Voya Investment Management LLC now owns 1,032,128 shares of the medical research company’s stock worth $61,215,000 after buying an additional 842,398 shares during the period. Janus Henderson Group PLC boosted its position in shares of Agilent Technologies by 2,135.0% during the second quarter. Janus Henderson Group PLC now owns 836,051 shares of the medical research company’s stock worth $49,587,000 after buying an additional 798,643 shares during the period. Vanguard Group Inc. boosted its position in shares of Agilent Technologies by 3.0% during the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock worth $1,310,374,000 after buying an additional 637,698 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Agilent Technologies by 187.3% during the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after buying an additional 483,721 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.